AIG
PRVB

American International Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

American International Group’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30,446
Closed -$734K – 3262
2023
Q1 		$734K Buy
30,446
+606
+2% +$7.61K ﹤0.01% 1399
2022
Q4 		$315K Buy
29,840
+1,829
+7% +$14.8K ﹤0.01% 1858
2022
Q3 		$126K Buy
28,011
+1,815
+7% +$8.27K ﹤0.01% 2423
2022
Q2 		$105K Sell
26,196
-1,340
-5% -$6.35K ﹤0.01% 2574
2022
Q1 		$202K Sell
27,536
-1,937
-7% -$11.6K ﹤0.01% 2231
2021
Q4 		$166K Sell
29,473
-882
-3% -$5.6K ﹤0.01% 2468
2021
Q3 		$194K Sell
30,355
-722
-2% -$4.64K ﹤0.01% 2446
2021
Q2 		$262 Buy
31,077
+151
+0.5% +$1.22K ﹤0.01% 2338
2021
Q1 		$325 Buy
30,926
+3,256
+12% +$45.8K ﹤0.01% 2089
2020
Q4 		$469 Sell
27,670
-793
-3% -$11.9K ﹤0.01% 1791
2020
Q3 		$365K Buy
28,463
+2,545
+10% +$32.1K ﹤0.01% 1765
2020
Q2 		$366K Buy
+25,918
New +$327K ﹤0.01% 1761

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

American International Group's PRVB Position: Q2 2023 in Review

American International Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 30,446 shares — an estimated $734K sold.

American International Group first reported a position in PRVB in Q2 2020 and held it in 12 quarters. The position peaked at $734K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • American International Group reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • American International Group sold 30,446 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $734K.
  • American International Group first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
  • American International Group's Provention Bio, Inc. Common Stock position peaked at $734K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on American International Group's 13F filing for Q2 2023, filed 4 Aug 2023.